|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Grady TJ, Gates MA and Boscoe FP:
Thyroid cancer incidence attributable to overdiagnosis in the
United States 1981–2011. Int J Cancer. 137:2664–2673. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aschebrook-Kilfoy B, Grogan RH, Ward MH,
Kaplan E and Devesa SS: Follicular thyroid cancer incidence
patterns in the United States, 1980–2009. Thyroid. 23:1015–1021.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmid D, Ricci C, Behrens G and Leitzmann
MF: Adiposity and risk of thyroid cancer: A systematic review and
meta-analysis. Obes Rev. 16:1042–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faam B, Ghaffari MA, Ghadiri A and Azizi
F: Epigenetic modifications in human thyroid cancer. Biomed Rep.
3:3–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ulisse S, Baldini E, Sorrenti S, Barollo
S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, et
al: In papillary thyroid carcinoma BRAFV600E is associated with
increased expression of the urokinase plasminogen activator and its
cognate receptor, but not with disease-free interval. Clin
Endocrinol (Oxf). 77:780–786. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SH, Roh JL, Gong G, Cho KJ, Choi SH,
Nam SY and Kim SY: Differences in the recurrence and survival of
patients with symptomatic and asymptomatic papillary thyroid
carcinoma: An observational study of 11,265 person-years of
follow-up. Thyroid. 26:1472–1479. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wobker SE, Kim LT, Hackman TG and Dodd LG:
Use of BRAF v600e immunocytochemistry on FNA direct smears of
papillary thyroid carcinoma. Cancer Cytopathol. 123:531–539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Benvenga S and Koch CA: Molecular pathways
associated with aggressiveness of papillary thyroid cancer. Curr
Genomics. 15:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Caronia LM, Phay JE and Shah MH: Role of
BRAF in thyroid oncogenesis. Clin Cancer Res. 17:7511–7517. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soares P, Trovisco V, Rocha AS, Lima J,
Castro P, Preto A, Máximo V, Botelho T, Seruca R and
Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are
alternative events in the etiopathogenesis of PTC. Oncogene.
22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anderson S, Bloom KJ, Vallera DU,
Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P,
Langland R, et al: Multisite analytic performance studies of a
real-time polymerase chain reaction assay for the detection of BRAF
V600E mutations in formalin-fixed, paraffin-embedded tissue
specimens of malignant melanoma. Arch Pathol Lab Med.
136:1385–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Lee KE, Myong JP, Park JH, Jeon
YK, Min HS, Park SY, Jung KC, Koo do H and Youn YK: BRAF V600E
mutation is associated with tumor aggressiveness in papillary
thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kalady MF, Dejulius KL, Sanchez JA, et al:
BRAF mutations in colorectal cancer are associated with distinct
clinical characteristics and worse prognosis. Dis Colon Rectum.
55:128–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong KK, Tsang YT, Deavers MT, Mok SC, Zu
Z, Sun C, Malpica A, Wolf JK, Lu KH and Gershenson DM: BRAF
mutation is rare in advanced-stage low-grade ovarian serous
carcinomas. Am J Pathol. 177:1611–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colombino M, Sperlongano P, Izzo F,
Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli
I, Agresti M, et al: BRAF and PIK3CA genes are somatically mutated
in hepatocellular carcinoma among patients from South Italy. Cell
Death Dis. 3:e2592012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kobayashi M, Sonobe M, Takahashi T,
Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL and Date H:
Clinical significance of BRAF gene mutations in patients with
non-small cell lung cancer. Anticancer Res. 31:4619–4623.
2011.PubMed/NCBI
|
|
25
|
Greenman C, Stephens P, Smith R, Dalgliesh
GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C,
et al: Patterns of somatic mutation in human cancer genomes.
Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weeraratna AT: RAF around the edges-the
paradox of BRAF inhibitors. N Engl J Med. 366:271–273. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su F, Viros A, Milagre C, Trunzer K,
Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT,
et al: RAS mutations in cutaneous squamous-cell carcinomas in
patients treated with BRAF inhibitors. N Engl J Med. 366:207–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yarchoan M, LiVolsi VA and Brose MS: BRAF
mutation and thyroid cancer recurrence. J Clin Oncol. 33:7–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rossi M, Buratto M, Tagliati F, Rossi R,
Lupo S, Trasforini G, Lanza G, Franceschetti P, Bruni S, Uberti
Degli E and Zatelli MC: Relevance of BRAF(V600E) mutation testing
versus RAS point mutations and RET/PTC rearrangements evaluation in
the diagnosis of thyroid cancer. Thyroid. 25:221–228. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Cheng X, Zhang Y, Li S, Cui H,
Zhang L, Shi R, Zhao Z, He C, Wang C, et al: Phosphorylation of
Mps1 by BRAFV600E prevents Mps1 degradation and contributes to
chromosome instability in melanoma. Oncogene. 32:713–723. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Samaan NA, Schultz PN, Hickey RC, Goepfert
H, Haynie TP, Johnston DA and Ordonez NG: The results of various
modalities of treatment of well differentiated thyroid carcinomas:
A retrospective review of 1599 patients. J Clin Endocrinol Metab.
75:714–720. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiloeches A and Marais R: Is BRAF the
Achilles' Heel of thyroid cancer? Clin Cancer Res. 12:1661–1664.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jinushi M, Chiba S, Baghdadi M, Kinoshita
I, Dosaka-Akita H, Ito K, Yoshiyama H, Yagita H, Uede T and Takaoka
A: ATM-mediated DNA damage signals mediate immune escape through
integrin-αvβ3-dependent mechanisms. Cancer Res. 72:56–65. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dhomen N, Reis-Filho JS, da Rocha Dias S,
Hayward R, Savage K, Delmas V, Larue L, Pritchard C and Marais R:
Oncogenic Braf induces melanocyte senescence and melanoma in mice.
Cancer Cell. 15:294–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perera PM, Wypasek E, Madhavan S,
Rath-Deschner B, Liu J, Nam J, Rath B, Huang Y, Deschner J, Piesco
N, et al: Mechanical signals control SOX-9, VEGF, and c-Myc
expression and cell proliferation during inflammation via
integrin-linked kinase, B-Raf, and ERK1/2-dependent signaling in
articular chondrocytes. Arthritis Res Ther. 12:R1062010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jeong D, Jeong Y, Park JH, Han SW, Kim SY,
Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, et al: BRAF (V600E)
mutation analysis in papillary thyroid carcinomas by peptide
nucleic acid clamp real-time PCR. Ann Surg Oncol. 20:759–766. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elisei R, Viola D, Torregrossa L, Giannini
R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, et
al: The BRAF(V600E) mutation is an independent, poor prognostic
factor for the outcome of patients with low-risk intrathyroid
papillary thyroid carcinoma: Single-institution results from a
large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Barollo S, Pennelli G, Vianello F,
Fernando Watutantrige S, Negro I, Boschin Merante I, Pelizzo MR,
Rugge M, Mantero F, Nacamulli D, et al: BRAF in primary and
recurrent papillary thyroid cancers: The relationship with (131)I
and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J
Endocrinol. 163:659–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pelizzo MR, Boschin IM, Barollo S,
Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC,
Pagetta C, et al: BRAF analysis by fine needle aspiration biopsy of
thyroid nodules improves preoperative identification of papillary
thyroid carcinoma and represents a prognostic factor. A
mono-institutional experience. Clin Chem Lab Med. 49:325–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xing M: Prognostic utility of BRAF
mutation in papillary thyroid cancer. Mol Cell Endocrinol.
321:86–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kebebew E, Weng J, Bauer J, Ranvier G,
Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence
and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.
246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ,
Lee NS, Park WC, Kim JS, Jung SS and Bae JS: Is the BRAF(V600E)
mutation useful as a predictor of preoperative risk in papillary
thyroid cancer? Am J Surg. 203:436–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sala E, Mologni L, Truffa S, Gaetano C,
Bollag GE and Gambacorti-Passerini C: BRAF silencing by short
hairpin RNA or chemical blockade by PLX4032 leads to different
responses in melanoma and thyroid carcinoma cells. Mol Cancer Res.
6:751–759. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Madhunapantula SV and Robertson GP: Is
B-Raf a good therapeutic target for melanoma and other
malignancies? Cancer Res. 68:5–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim SW, Kim HK, Lee JI, Jang HW, Choe JH,
Kim JH, Kim JS, Hur KY, Kim JH and Chung JH: ERK phosphorylation is
not increased in papillary thyroid carcinomas with BRAF(V600E)
mutation compared to that of corresponding normal thyroid tissues.
Endocr Res. 38:89–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zuo H, Nakamura Y, Yasuoka H, Zhang P,
Nakamura M, Mori I, Miyauchi A and Kakudo K: Lack of association
between BRAF V600E mutation and mitogen-activated protein kinase
activation in papillary thyroid carcinoma. Pathol Int. 57:12–20.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
50
|
Melillo RM, Castellone MD, Guarino V, De
Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R,
Kruhoffer M, et al: The RET/PTC-RAS-BRAF linear signaling cascade
mediates the motile and mitogenic phenotype of thyroid cancer
cells. J Clin Invest. 115:1068–1081. 2005. View Article : Google Scholar : PubMed/NCBI
|
